Chong Kun Dang Pharmaceutical Corp. (KRX:185750)

KRX:185750 Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,625,884	1,586,431	1,669,404	1,488,345	1,343,559	1,303,006
Other Revenue	-	-0	-	-	-	-
Revenue	1,625,884	1,586,431	1,669,404	1,488,345	1,343,559	1,303,006
Revenue Growth (YoY)	-2.39%	-4.97%	12.16%	10.78%	3.11%	20.72%
Cost of Revenue	1,102,398	1,053,820	1,007,203	945,705	847,741	813,866
Gross Profit	523,486	532,611	662,202	542,639	495,818	489,140
Selling, General & Admin	269,925	267,793	256,595	237,936	220,982	202,292
Research & Development	150,935	143,914	140,235	176,325	163,277	146,664
Other Operating Expenses	12,367	12,605	11,694	11,387	12,206	10,184
Operating Expenses	442,403	433,150	415,602	432,733	401,060	365,204
Operating Income	81,082	99,462	246,599	109,906	94,759	123,936
Interest Expense	-8,072	-8,319	-9,271	-6,847	-4,030	-3,871
Interest & Investment Income	11,363	12,691	6,028	2,333	759.37	1,387
Earnings From Equity Investments	-	-	798.36	-460.38	-603.47	-
Currency Exchange Gain (Loss)	964.11	2,918	-2,356	-2,524	-183.41	-569.56
Other Non Operating Income (Expenses)	132.14	-1,208	-1,777	838.33	-10,128	371.38
EBT Excluding Unusual Items	85,470	105,543	240,021	103,246	80,573	121,253
Gain (Loss) on Sale of Investments	-3,345	-2,764	1,465	-2,223	-98.87	517.38
Gain (Loss) on Sale of Assets	137.99	154	111.88	54.05	119.34	68.18
Asset Writedown	-40.66	-923.8	-	-3,912	-	-
Pretax Income	82,222	102,009	241,598	97,165	80,594	121,839
Income Tax Expense	-14,425	-9,433	27,996	17,187	38,237	31,434
Earnings From Continuing Operations	96,648	111,442	213,602	79,978	42,356	90,405
Minority Interest in Earnings	-1,366	-2,369	-1,081	975.58	363.91	1,228
Net Income	95,282	109,073	212,521	80,953	42,720	91,633
Net Income to Common	95,282	109,073	212,521	80,953	42,720	91,633
Net Income Growth	-52.89%	-48.68%	162.52%	89.50%	-53.38%	70.06%
Shares Outstanding (Basic)	13	13	14	13	14	14
Shares Outstanding (Diluted)	13	13	14	13	14	14
Shares Change (YoY)	-5.33%	-5.20%	3.79%	-1.77%	-0.73%	-0.06%
EPS (Basic)	7211.39	8234.46	15210.37	6013.65	3117.38	6637.55
EPS (Diluted)	7211.39	8234.46	15210.37	6013.65	3117.38	6637.55
EPS Growth	-50.24%	-45.86%	152.93%	92.91%	-53.03%	70.17%
Free Cash Flow	-19,022	25,815	276,942	22,836	-35,339	71,684
Free Cash Flow Per Share	-1439.71	1948.91	19821.04	1696.38	-2578.75	5192.55
Dividend Per Share	1100.000	1100.000	-	-	-	-
Gross Margin	32.20%	33.57%	39.67%	36.46%	36.90%	37.54%
Operating Margin	4.99%	6.27%	14.77%	7.38%	7.05%	9.51%
Profit Margin	5.86%	6.88%	12.73%	5.44%	3.18%	7.03%
Free Cash Flow Margin	-1.17%	1.63%	16.59%	1.53%	-2.63%	5.50%
EBITDA	122,680	139,234	283,629	143,504	122,241	147,721
EBITDA Margin	7.54%	8.78%	16.99%	9.64%	9.10%	11.34%
D&A For EBITDA	41,598	39,772	37,030	33,598	27,482	23,786
EBIT	81,082	99,462	246,599	109,906	94,759	123,936
EBIT Margin	4.99%	6.27%	14.77%	7.38%	7.05%	9.51%
Effective Tax Rate	-	-	11.59%	17.69%	47.45%	25.80%
Advertising Expenses	-	74,740	69,707	60,364	51,329	45,629

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.